Cancer History Considerations

Why Cancer History Matters

Cancer history matters most for growth hormone (GH) and IGF-1 pathway peptides, and for a few approved peptide drugs with tumor warnings. The contraindicated conditions overview explains how labels sort contraindications.

The IGF-1 and Cancer Connection

Mechanism of Concern

Factor	Relationship	Significance
IGF-1 receptor	Present on many cancers	Growth stimulation
Cell proliferation	IGF-1 promotes (lab studies)	Tumor growth
Apoptosis inhibition	IGF-1 suppresses (lab studies)	Cell survival
Angiogenesis	GH/IGF-1 may promote	Tumor support

These links come from lab research, not human outcome data.

Epidemiological Data

In UK Biobank, an observational cohort of about 394,000 adults (mean follow-up 6.9 years), higher IGF-1 was linked to modestly higher risk of colorectal, breast, prostate and thyroid cancer. Reverse causation couldn't be ruled out.

GH-treated childhood cancer survivors had about twice the rate of second tumors in one observational cohort, an excess that shrank with longer follow-up. A 2014 analysis found no significant rise in brain tumors.

Absolute Contraindications on Drug Labels

As of October 2026, the US labels for somatropin (Genotropin) and tesamorelin (Egrifta WR) list active malignancy as a contraindication and say a past cancer should be inactive and fully treated first. Egrifta WR also lists pregnancy. Research vials sold under these names aren't equivalent prescription medicines.

The semaglutide (Wegovy) and tirzepatide (Zepbound) labels carry a boxed warning for thyroid C-cell tumors seen in rodents, with human relevance unknown. Both are contraindicated with a personal or family history of medullary thyroid carcinoma (MTC) or MEN 2.

Active Cancer

Situation	Label Position	Rationale
Current diagnosis	Contraindicated (GH, tesamorelin)	Growth promotion risk
Active treatment	Complete first	Recurrence risk
MTC or MEN 2 history	Contraindicated (GLP-1 drugs)	Rodent tumors

Relative Contraindications (Editorial Caution)

Research peptides have no label, so these cautions for GH secretagogues such as MK-677 are editorial inferences. The year cutoffs come from peptide guides, not published thresholds.

Cancer in Remission

Duration	Risk Level	Consideration
<2 years	High	Generally avoided in guides
2-5 years	Moderate	Case-by-case
5-10 years	Lower	Oncologist input
>10 years	Lowest	Considered with surveillance

Family History

Family History	Risk Level	Approach
Hereditary syndromes	Highest	Flagged on the somatropin label

Peptides Outside the GH/IGF-1 Pathway

BPC-157 and TB-500 don't act mainly through GH or IGF-1. That doesn't make them safe after cancer; no study has included cancer survivors. Their angiogenesis concern is theoretical and preclinical: a 2025 review notes BPC-157 upregulates VEGF in animal and cell studies, though other preclinical work found it suppressed VEGF-driven tumor growth. Thymosin beta-4, the parent protein of TB-500, promotes angiogenesis in lab studies and is overexpressed in colorectal cancer stem cells.

Medical Consultation

An oncologist can judge whether a specific cancer is thought to be IGF-1 sensitive. The somatropin label also notes GH can unmask glucose intolerance, which the diabetes page covers.

What We Still Don't Know

Nobody has measured recurrence in survivors using unapproved GH secretagogues or recovery peptides.